PT2822947T - Sais de arginina de um agonista de tlr7 - Google Patents

Sais de arginina de um agonista de tlr7

Info

Publication number
PT2822947T
PT2822947T PT137081428T PT13708142T PT2822947T PT 2822947 T PT2822947 T PT 2822947T PT 137081428 T PT137081428 T PT 137081428T PT 13708142 T PT13708142 T PT 13708142T PT 2822947 T PT2822947 T PT 2822947T
Authority
PT
Portugal
Prior art keywords
tlr7 agonist
arginine salts
arginine
salts
tlr7
Prior art date
Application number
PT137081428T
Other languages
English (en)
Portuguese (pt)
Inventor
Kay Dodd Stephanie
Jain Siddartha
Original Assignee
Glaxosmithkline Biologicals Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals Sa filed Critical Glaxosmithkline Biologicals Sa
Publication of PT2822947T publication Critical patent/PT2822947T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/39Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PT137081428T 2012-03-07 2013-03-07 Sais de arginina de um agonista de tlr7 PT2822947T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261608011P 2012-03-07 2012-03-07

Publications (1)

Publication Number Publication Date
PT2822947T true PT2822947T (pt) 2016-09-26

Family

ID=47843276

Family Applications (1)

Application Number Title Priority Date Filing Date
PT137081428T PT2822947T (pt) 2012-03-07 2013-03-07 Sais de arginina de um agonista de tlr7

Country Status (18)

Country Link
US (1) US9320748B2 (enExample)
EP (1) EP2822947B1 (enExample)
JP (1) JP6325986B2 (enExample)
CN (1) CN104203946B (enExample)
AU (1) AU2013229466A1 (enExample)
CA (1) CA2865759C (enExample)
CY (1) CY1118091T1 (enExample)
DK (1) DK2822947T3 (enExample)
ES (1) ES2597755T3 (enExample)
HR (1) HRP20161354T1 (enExample)
HU (1) HUE030175T2 (enExample)
LT (1) LT2822947T (enExample)
MX (1) MX346678B (enExample)
PL (1) PL2822947T3 (enExample)
PT (1) PT2822947T (enExample)
RU (1) RU2014140336A (enExample)
SI (1) SI2822947T1 (enExample)
WO (1) WO2013131985A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010290896B2 (en) 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
US20140112950A1 (en) 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant
JP6345603B2 (ja) 2012-03-08 2018-06-20 ノバルティス アーゲー 追加免疫ワクチンのアジュバント化された処方物
AU2015238512B2 (en) 2014-03-26 2018-02-01 Glaxosmithkline Biologicals S.A. Mutant staphylococcal antigens
EP3061826A1 (en) 2015-02-27 2016-08-31 Novartis AG Flavivirus replicons
WO2021178306A1 (en) * 2020-03-01 2021-09-10 Dynavax Technologies Corporation Coronavirus vaccines comprising a tlr9 agonist
US20220280482A1 (en) * 2021-03-06 2022-09-08 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699474B1 (en) 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
EP0967279B1 (en) 1992-03-02 2008-01-02 Novartis Vaccines and Diagnostics S.r.l. Helicobacter pylori cytotoxin useful for vaccines and diagnostics
FR2718452B1 (fr) 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
DE69529219T2 (de) 1994-07-01 2003-11-06 Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville Helicobacter proteine und impstoffe
GB2324093A (en) 1996-01-04 1998-10-14 Rican Limited Helicobacter pylori bacterioferritin
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
CA2414884A1 (en) 2000-07-03 2002-01-10 Chiron S.P.A. Immunisation against chlamydia pneumoniae
FR2827605B1 (fr) 2001-07-20 2004-07-16 Pf Medicament Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
EP2168596B1 (en) 2001-12-12 2012-05-23 Novartis Vaccines and Diagnostics S.r.l. Immunisation against chlamydia trachomatis
GB0211118D0 (en) 2002-05-15 2002-06-26 Polonelli Luciano Vaccines
CN1809380B (zh) 2002-10-11 2010-05-12 启龙有限公司 广泛防御高毒性脑膜炎球菌谱系的多肽-疫苗
CA2526106A1 (en) 2003-06-26 2005-01-13 Chiron Corporation Immunogenic compositions for chlamydia trachomatis
BRPI0508365A (pt) 2004-03-02 2007-07-24 Chiron Corp composições imunogênicas para chlamydia pneumoniae
SI2351772T1 (sl) 2005-02-18 2016-11-30 Glaxosmithkline Biologicals Sa Proteini in nukleinske kisline iz Escherichia coli povezane z meningitisom/sepso
JP2008530245A (ja) 2005-02-18 2008-08-07 ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド 尿路病原性菌株由来の抗原
US8133973B2 (en) 2005-05-12 2012-03-13 Novartis Vaccines And Diagnostics, S.R.L. Immunogenic compositions for Chlamydia trachomatis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
US8481057B2 (en) 2005-12-22 2013-07-09 Novartis Vaccines & Diagnostics Srl Chlamydial antigens
EP2586790A3 (en) 2006-08-16 2013-08-14 Novartis AG Immunogens from uropathogenic Escherichia coli
BR122016015627A2 (pt) 2007-10-19 2018-10-30 Novartis Ag kit, composição antigênica liofilizada e método para preparação de uma composição imunogênica
NZ612315A (en) 2009-04-14 2014-10-31 Novartis Ag Compositions for immunising against staphylococcus aureus
US8609106B2 (en) 2009-06-01 2013-12-17 Novartis Ag Combinations of pneumococcal RrgB clades
CA2765112A1 (en) * 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
JP2013502918A (ja) 2009-08-27 2013-01-31 ノバルティス アーゲー 髄膜炎菌fHBP配列を含むハイブリッドポリペプチド
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
AU2010290896B2 (en) * 2009-09-02 2014-07-03 Glaxosmithkline Biologicals S.A. Immunogenic compositions including TLR activity modulators
MX343914B (es) 2010-09-01 2016-11-18 Glaxosmithkline Biologicals Sa Adsorcion de inmunopotenciadores en sales metalicas insolubles.
WO2012103421A1 (en) 2011-01-27 2012-08-02 Novartis Ag Adjuvant nanoemulsions with crystallisation inhibitors
BR112014004782A2 (pt) * 2011-09-01 2017-03-21 Novartis Ag formulações adjuvantes de antígenos de staphylococcus aureus

Also Published As

Publication number Publication date
MX346678B (es) 2017-03-29
CA2865759C (en) 2020-07-21
SI2822947T1 (sl) 2016-10-28
HUE030175T2 (en) 2017-04-28
RU2014140336A (ru) 2016-04-27
HRP20161354T1 (hr) 2016-12-02
CN104203946B (zh) 2017-03-22
US9320748B2 (en) 2016-04-26
ES2597755T3 (es) 2017-01-20
EP2822947A1 (en) 2015-01-14
CA2865759A1 (en) 2013-09-12
CN104203946A (zh) 2014-12-10
US20150125475A1 (en) 2015-05-07
MX2014010423A (es) 2014-09-22
DK2822947T3 (en) 2016-09-19
EP2822947B1 (en) 2016-08-03
JP6325986B2 (ja) 2018-05-16
CY1118091T1 (el) 2017-06-28
LT2822947T (lt) 2016-10-10
AU2013229466A1 (en) 2014-09-04
JP2015511957A (ja) 2015-04-23
PL2822947T3 (pl) 2017-01-31
WO2013131985A1 (en) 2013-09-12

Similar Documents

Publication Publication Date Title
ZA201401884B (en) New dihydroquinoline-2-one derivatives
SI2822947T1 (sl) Argininske soli TLR7 agonista
EP2970081A4 (en) SALTS OF TREPROSTINIL
GB201304499D0 (en) Carcainium Salts
SG11201401937YA (en) New aryl-quinoline derivatives
ZA201409497B (en) Tetrahydroquinazolinone derivatives as parp inhibitors
ZA201308401B (en) Substituted benzamide derivatives
PT2838883T (pt) Novos derivados de fenil-tetra-hidroisoquinolina
ZA201409327B (en) Solid forms of a pyrido-pyrimidinium inner salt
IL231269B (en) Preparations for the treatment of HIV
ZA201406238B (en) Crystalline form of a succinate salt
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
EP2782902A4 (en) DERIVATIVES FROM PHENOXYISOBUTTERIC ACID
IL237382A0 (en) Salts of a benzothiazolone compound as beta-2 adrenergic receptor agonists
PL2760822T3 (pl) Sole desfezoterodyny
ZA201308872B (en) Use of a dinitromethane salt
GB201100332D0 (en) Monty Izofit
ZA201205358B (en) Use of a salt of bistetrazolylamine
GB201106819D0 (en) Novel salts
GB201209895D0 (en) Use of a composition
GB201219868D0 (en) Facilitating completion of a form
GB201204590D0 (en) Prodrugs of thiazolamine compounds